In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.
Investigators concluded that reducing peripheral serotonin concentrations with rodatristat ethyl negatively impacted pulmonary haemodynamics and cardiac function in patients with PAH.